Abstract
Introduction: The aim of this study was to assess the relationship between olfactory cleft width/volume and COVID-19-related anosmia. Methods: This study consisted of PCR-proven COVID-19 patients. Cases with COVID-19-related anosmia constituted Group 1 and cases without any olfactory dysfunction (OD) throughout COVID-19 infection or after recovery constituted Group 2. A total of 50 patients were included in the study, comprising 24 cases in Group 1 and 26 cases in Group 2. Group 1 patients underwent a 4-item-odor identification test during active symptoms and a Sniffin’ Sticks test after reconversion of PCR results to negative. All patients in Group 2 also underwent the Sniffin’ Stick test to document normosmia. All cases had paranasal sinus CT performed. Olfactory cleft widths and olfactory volumes were measured. The differences in width and volume between groups and the correlation with odor test scores (threshold-discrimination-identification [TDI]) were calculated. In addition, regression analyzes analysis was performed for cleft widths, volumes, and TDI scores according to age. Results: Olfactory cleft widths and olfactory volumes were significantly higher in Group 1 than those in Group 2 (p = 0.001; p < 0.01). There was a significant negative correlation between total TDI scores and olfactory cleft widths and total olfactory volumes (r = −0.665; r = −0.731, respectively). Patients younger than 40 years of age had significantly higher right olfactory cleft width, left olfactory cleft width, and olfactory cleft volume than those in patients older than 40 years of age (p = 0.004, p = 0.005, p = 0.003; p < 0,01, respectively). However, patients younger than 40 years of age had a significantly lower total TDI score and in all other values individually (t-d-i) than those in patients older than 40 years of age (p = 0.004; p < 0.01). Conclusion: Patients with COVID-19-related OD had larger olfactory cleft width and volumes than those without OD in this study. Total TDI score was found to be inversely correlated with cleft width and volume.
References
1.
Parma
V
, Ohla
K
, Veldhuizen
MG
, Niv
MY
, Kelly
CE
, Bakke
AJ
, More than smell-COVID-19 is associated with severe impairment of smell, taste, and chemesthesis
. Chem Senses
. 2020
;45
(7
):609
–22
. .2.
Bagheri
SH
, Asghari
A
, Farhadi
M
, Shamshiri
AR
, Kabir
A
, Kamrava
SK
, Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak in Iran
. Med J Islam Repub Iran
. 2020
;34
(62
);446
–52
. .3.
Gane
SB
, Kelly
C
, Hopkins
C
. Isolated sudden onset anosmia in COVID19 infection. A novel syndrome?
Rhinology
. 2020
;58
(3
):299
–301
.4.
Giacomelli
A
, Pezzati
L
, Conti
F
, Bernacchia
D
, Siano
M
, Oreni
L
, Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study
, Clin Infect Dis
. 2020
;71
(15
):889
–90
. .5.
Vroegop
AV
, Eeckels
AS
, Van Rompaey
V
, Abeele
VD
, Schiappoli
M
, Alobid
I
, COVID-19 and olfactory dysfunction – an ENT perspective to the current COVID-19 pandemic
. B-ENT
. 2020
;16
(1
):81
–5
.6.
Çetinkaya
EA
, Selçuk
ÖT
, Eyigör
H
, Gür
ÖE
. COVID-19 and anosmia
. ENT-HNS
. 2020
;28
(Suppl l
):S61
–S63
.7.
Hjelmesæth
J
, Skaare
D
. Loss of smell or taste as the only symptom of COVID-19
. Tidsskr Nor Laegeforen
. 2020
;140
:7
.8.
Heidari
F
, Karimi
E
, Firouzifar
M
, Khamushian
P
, Ansari
R
, Mohammadi Ardehali
M
, Anosmia as a prominent symptom of COVID-19 infection
. Rhinology
. 2020
;58
(3
):302
–3
. .9.
Hopkins
C
, Surda
P
, Kumar
N
. Presentation of new onset anosmia during the COVID-19 pandemic
. Rhinology
. 2020
;58
(3
):295
–8
. .10.
Lechien
JR
, Cabaraux
P
, Chiesa-Estomba
CM
, Khalife
M
, Plzak
J
, Hans
S
, Objective olfactory testing in patients presenting with sudden onset olfactory dysfunction as the first manifestation of confirmed COVID-19 infection
. MedRxiv
. 2020
.11.
Yan
CH
, Faraji
F
, Prajapati
DP
, Boone
CE
, DeConde
AS
. Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms
. Int Forum Allergy Rhinol
. 2020
;10
(7
):806
–13
. .12.
Yildirim
D
, Altundag
A
, Tekcan Sanli
DE
, Bakir
A
, Eryurekli
A
, Alis
D
, A new perspective on imaging of olfactory dysfunction: does size matter?
Eur J Radiol
. 2020
;132
:109290
. .13.
Goncalves
S
, Goldstein
BJ
. Pathophysiology of olfactory disorders and potential treatment strategies
. Curr Otorhinolaryngol Rep
. 2020
;4
(2
):115
–21
. .14.
Altundag
A
, Yıldırım
D
, Tekcan Sanli
DE
, Cayonu
M
, Kandemirli
SD
, Necati Sanli
A
, Olfactory cleft measurements and COVID-19-related anosmia
. Otolaryngol Head Neck Surg
. 2020
.15.
Mitrano
DA
, Houle
SE
, Pearce
P
, Quintanilla
RM
, Lockhart
BK
, Genovese
BC
, Olfactorydysfunction in the 3xTg-AD model of Alzheimer’s disease
. IBRO NeurosciRep
. 2020
;10
:51
–61
.16.
Zou
YM
, Lu
D
, Liu
LP
, Zhang
HH
, Zhou
YY
. Olfactory dysfunction in Alzheimer’s disease
. Neuropsychiatr Dis Treat
. 2016
;12
:869
–75
. .17.
Hummel
T
, Sekinger
B
, Wolf
SR
, Pauli
E
, Kobal
G
. Sniffin’ sticks’: olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold
. Chem Senses
. 1997
;22
(1
):39
–52
.18.
Kobal
G
, Klimek
L
, Wolfensberger
M
, Gudziol
H
, Temmel
A
, Owen
CM
, Multicenter investigation of 1,036 subjects using a standardized method for the assessment of olfactory function combining tests of odor identification, odor discrimination, and olfactory thresholds
. Eur Arch Otorhinolaryngol
. 2000
;257
(4
):205
–11
. .19.
Wolfensberger
M
, Schnieper
I
, Welge-Lüssen
A
. Sniffin’ sticks: a new olfactory test battery
. Acta Otolaryngol
. 2000
;120
(2
):303
–6
. .20.
Hummel
T
, Kobal
G
, Gudziol
H
, Mackay-Sim
A
. Normative data for the “Sniffin’ sticks”: including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects
. Eur Arch Otorhinolaryngol
. 2007
;264
(3
):237
–43
.21.
Tekeli
H
, Altundağ
A
, Salihoğlu
M
, Cayönü
M
, Kendirli
MT
. The applicability of the “Sniffin’ sticks” olfactory test in a Turkish population
. Med Sci Monit
. 2013
;19
:1221
–6
. .22.
Worley
ML
, Schlosser
RJ
, Soler
ZM
, Dubno
JR
, Eckert
MA
. Age-related differences in olfactory cleft volume in adults: a computational volumetric study
. Laryngoscope
. 2020
;129
(2
):E55
–60
. .23.
Holbrook
EH
, Wu
E
, Curry
WT
, Lin
DT
, Schwob
JE
. Immunohistochemical characterization of human olfactory tissue
. Laryngoscope
. 2011
;121
(8
):1687
–701
. .24.
Hummel
T
, Whitcroft
KL
, Andrews
P
, Altundag
A
, Cinghi
C
, Costanzo
RM
, Position paper on olfactory dysfunction
. Rhinol Suppl
. 2017
;54
(26
):1
–30
. .25.
Hawkes
C
. Olfaction in neurodegenerative disorder
. Adv Otorhinolaryngol
. 2006
;63
:133
–51
. .26.
Ajmani
GS
, Suh
HH
, Pinto
JM
. Effects of ambient air pollution exposure on olfaction: a review
. Environ Health Perspect
. 2016
;124
(11
):1683
–93
. .27.
Altundag
A
, Temirbekov
D
, Haci
C
, Yildirim
D
, Cayonu
M
. Olfactory cleft width and volume: possible risk factors for postinfectious olfactory dysfunction
. Laryngoscope
. 2021
;131
(1
):5
–9
. .28.
Sanli
DET
, Altundag
A
, Kandemirli
SG
, Yildirim
D
, Sanli
AN
, Saatci
O
, Relationship between disease severity and serum IL-6 levels in COVID-19 anosmia
. Am J Otolaryngol
. 2021 Jan–Feb
;42
(1
):102796
. .29.
Torabi
A
, Mohammadbagheri
E
, Akbari Dilmaghani
N
, Bayat
AH
, Fathi
M
, Vakili
K
, Proinflammatory cytokines in the olfactory mucosa result in COVID-19 induced anosmia
. ACS Chem Neurosci
. 2020
;11
(13
):1909
–13
. .30.
Yazdanpanah
N
, Saghazadeh
A
, Rezaei
N
. Anosmia: a missing link in the neuroimmunology of coronavirus disease 2019 (COVID-19)
. Rev Neurosci
. 2020
;31
(7
):691
–701
. .31.
Baig
AM
, Khaleeq
A
, Ali
U
, Syeda
H
. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms
. ACS Chem Neurosci
. 2020
;11
(7
):995
–8
. .32.
Bilinska
K
, Jakubowska
P
, Von Bartheld
CS
, Butowt
R
. Expression of the SARS-CoV-2 entry proteins, ACE2 and TMPRSS2, in cells of the olfactory epithelium: identification of cell types and trends with age
. ACS Chem Neurosci
. 2020
;11
(11
):1555
–62
. .33.
Brann
DH
, Tsukahara
T
, Weinreb
C
, Lipovsek
M
, Van den Berge
K
, Gong
B
, Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia
. Sci Adv
. 2020
;6
(31
):eabc5801
. .34.
Fodoulian
L
, Tuberosa
J
, Rossier
D
, Landis
BN
, Carleton
A
, Rodriguez
I
. SARS-CoV-2 receptor and entry genes are expressed by sustentacular cells in the human olfactory neuroepithelium
. BioRxiv
. 2020
.35.
Sánchez-Vallecillo
MV
, Fraire
ME
, Baena-Cagnani
C
, Zernotti
ME
. Olfactory dysfunction in patients with chronic rhinosinusitis
. Int J Otolaryngol
. 2012
;2012
(2012
):327206
. .36.
Meng
X
, Deng
Y
, Dai
Z
, Meng
Z
. COVID-19 and anosmia: a review based on up-to-date knowledge
. Am J Otolaryngol
. 2020
;41
(5
):102581
. .37.
Long
B
, Brady
WJ
, Koyfman
A
, Gottlieb
M
. Cardiovascular complications in COVID-19
. Am J Emerg Med
. 2020
;38
(7
):1504
–7
. .38.
Carod-Artal
FJ
. Neurological complications of coronavirus and COVID-19
. Rev Neurol
. 2020
;70
(9
):311
–22
. .39.
Kandemirli
SG
, Dogan
L
, Sarikaya
ZT
, Kara
S
, Akinci
C
, Kaya
D
, Brain MRI findings in patients in the intensive care unit with COVID-19 infection
. Radiology
. 2020
;297
(1
):E232
–5
. .40.
Ylikoski
J
, Markkanen
M
, Mäkitie
A
. Pathophysiology of the COVID-19 – entry to the CNS through the nose
. Acta Otolaryngol
. 2020
;140
(10
):886
–9
. .41.
Lechien
JR
, Chiesa-Estomba
CM
, De Siati
DR
, Horoi
M
, Le Bon
SD
, Rodriguez
A
, Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study
. Eur Arch Otorhinolaryngol
. 2020
;277
(8
):2251
–61
. .42.
Worley
ML
, Schlosser
RJ
, Soler
ZM
, Dubno
JR
, Eckert
MA
. Age-relateddifferences in olfactorycleftvolume in adults: a computational volumetric study
. Laryngoscope
. 2019
;129
(2
):E55
–E60
.© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
